Geron Corporation (NASDAQ:GERN) reported its last quarter results on 11/03/2016. This Company belongs to Medical sector.
In the last trading session, The Company traded 1.68 Million shares. The Stock Market opened sessions at 2.2 and closed at 2.2. There was a stock decrease by -0.45 percent.
According to Yahoo Finance, the price target for the company which analysts are aiming is 5. The 1-year price target of the company is 4.38.
Investors expected a price target of -0.06 for this quarter. Zacks Investment Research gave Geron Corporation (NASDAQ:GERN) a rating of 1.67 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.
Considering the performance, Geron Corporation (NASDAQ:GERN)’s shares have the potential to reach a high EPS of -0.05 per share, and a low EPS of -0.07 per share in the current quarter. All of these Earnings estimates are a consensus recommendation of 5 Analysts. According to them, the median (average) EPS the company could deliver is -0.06/share. While the actual EPS the company reported in the same quarter previous year was -0.05/share.
For the quarter ending 08/03/2016, The Analyst projected that the company could deliver EPS of -0.07 while the company provided its Actual EPS of -0.05 showing a difference of 0.02 Percent between the Estimated and Actual EPS. Hence, the surprise factor was 28.6 percent.
Analysts estimated $-0.06/share for the previous Quarter, where Geron Corporation (NASDAQ:GERN) reported Actual EPS of $-0.02/share with the difference of 0.04 percent and a surprise of 66.7 percent.
The 3 analysts offering 12-month price forecasts for Geron Corp have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 2.50. The median estimate represents a +127.27% increase from the last price of 2.20.
Geron Corporation (NASDAQ:GERN) topped its 52-week high price target of 3.64 on Jan 13, 2016. The company reached a 52-week low at 1.81 on Nov 3, 2016.
The company’s stock currently has 350.11 Million in market capitalization. The volatility rate is 6.30% percent and 4.85% percent each. Price per earning (ttm) stands at 0.
Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.